Jeffrey Stein - Mar 27, 2023 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: President & CEO, Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Stock symbol: CDTX
Transactions as of: Mar 27, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/29/2023, 05:30 PM
Previous filing: Feb 23, 2023
Next filing: Jun 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDTX	Common Stock	Award	$0	+272K	+29.2%	$0.00	1.2M	Mar 27, 2023	Direct	F1, F2
holding	CDTX	Common Stock						282K	Mar 27, 2023	By trust
holding	CDTX	Common Stock						42K	Mar 27, 2023	By son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Employee Stock Option (right to buy)	Award	$0	+544K		$0.00	544K	Mar 27, 2023	Common Stock	544K	$1.01	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents time-based Restricted Stock Units (RSUs) granted on March 27, 2023. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2024, 2025, and 2026, subject to continuous service through each such vesting date.
F2	Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on May 20, 2022 and November 18, 2022.
F3	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.